argenx SE at Goldman Sachs Global Healthcare Conference Transcript
Okay. Ladies and gentlemen, welcome to our next session where I'm very pleased to be joined by the team from argenx. I'm [Nick Hallett], I work in the European biopharma team in London. I'm joined today by Keith Woods, Chief Operating Officer; and Beth DelGiacco, the VP of IR. So first of all, welcome to both. It's great to have you here.
Thank you for having us. Pleasure to be here.
Questions & Answers
Perhaps, Keith, if we could start, if you could just sort of give a high-level overview of where argenx stands today, where your therapeutic area of focus is?
Sure. So as you know, at argenx, we were born out of engineering antibodies for other companies. Our ambition has expanded into clinical development, and we've kept some of those discoveries in-house first and foremost, is efgartigimod, VYVGART. We now have commercially launched VYVGART in the U.S. and Japan. So we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
